Compare Cronos Group Inc (CRON) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Tempus AI — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Tempus AI trades at $70.55 (market cap $12.77B). The key difference: Tempus AI is far larger — about 10.6× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Tempus AI for 22 Days on average.
| CRON | TEM | |
|---|---|---|
Market Cap | $1.20B | $12.77B |
Volume | 450,387 | 8,980,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $3.55 | $99.28 |
52-Week Low | $2.30 | $41.55 |
Typical Hold Time | 22 Days | 22 Days |
Enterprise Value | $401.73M | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
